Skip to main content

Table 2 Selected clinical characteristics according to active and non-active androgen deprivation therapy and propensity score based inverse weight double robust estimation with death as outcome

From: Impact of androgen deprivation therapy on mortality of prostate cancer patients with COVID-19: a propensity score-based analysis

Characteristic

Active (n = 156)

Non-active (n = 43)

Total (n = 199)

Pa

Standardized difference

Unweighted

Weighted

Age

≤ 75 years

79 (50.6)

25 (58.1)

104 (52.3)

0.395

− 0.151

0.113

> 75 years

77 (49.4)

18 (41.9)

95 (47.7)

   

Comorbidities

Heart Disease

60 (38.5)

21 (48.8)

81 (40.7)

0.226

0.210

− 0.018

Diabetes

37 (23.7)

12 (27.9)

49 (24.6)

0.555

0.096

− 0.031

Neurologic disease

8 (5.1)

3 (7)

11 (5.5)

0.706

0.078

0.141

Asthma

3 (1.9)

3 (7)

6 (3)

0.116

0.247

− 0.006

Chronic lung disease

14 (9)

3 (7)

17 (8.5)

1

− 0.074

0.065

Nephropathy

12 (7.7)

9 (20.9)

21 (10.6)

0.022

0.385

− 0.023

Critical presentation

48 (30.8)

15 (34.9)

63 (31.7)

0.711

0.088

− 0.052

Southeast

94 (60.3)

27 (62.8)

121 (60.8)

0.861

0.052

0.063

Palliative treatment

142 (91)

37 (86.1)

179 (89.9)

0.39

− 0.157

0.011

Outcome

Hospital discharge

56 (35.9)

11 (25.6)

67 (33.7)

0.274

  

Death

100 (64.1)

32 (74.4)

132 (66.3)

   
  1. aFisher exact test